Letters to the Editor ignated f-amyloidopathy (APP 717).' We screened 85 cases of early onset AD to estimate the frequency of this mutation.
< 60 years, with a mean (SD) of 54-0(4-9). Sixty four cases had no affected first or second degree relatives, 21 were familial with at least one first or second degree relative with AD.
DNA was extracted from blood leucocytes, and exon 17 of APP gene was amplified by the polymerase chain reaction (PCR), according to Goate et al.2 Since the (APP 717: Val->Ile) mutation creates a BclI restriction site allowing its direct detection,2 the PCR product was digested with the BclI restriction enzyme and analysed on a 2% agarose gel. The enzyme did not recognise the mutant BclI site in any of our cases, whereas it digested the PCR product of an in vitro generated exon 17 with the (APP717: Val->Ile) mutation. This agrees with the studies ofVan Duijn et al5 and Schellenberg et al,6 including patients with a higher age of onset. Combining the results of all studies on early onset patients of Caucasian origin,2468 it may be concluded that for a confidence interval of 95%, less than 2-6% of isolated cases, and between 0 3 and 5-3% of familial cases, would have this mutation.
Two other missense mutations have, however, also been found in the same codon of APP gene9 supporting the hypothesis of allelic heterogeneity in early onset AD. We cannot therefore exclude the presence of another APP gene mutation in our sample.
Even if the (APP 717 Val->Ile) mutation is of poor diagnostic value, the identification of other mutations within the same gene will establish a clear molecular classification and contribute to the understanding of the pathogenesis of the disease. A serotonergic disturbance is suggested by reduced CSF5-HIAA in Baltic myoclonus and the antimyoclonic effect of L-tryptophan plus a monoamine oxidase inhibitor or 5-hydroxy-L-tryptophan in some patients. ' The problem is that these observations do not point to a specific locus of abnormality in the 5-HT system. Serotonin (5-HT) receptor pharmacology has advanced rapidly, identifying multiple 5-HT receptors types. Only a few have been studied in experimental myoclonus. In rats, the full 5-HT receptor agonist 8-OH-DPAT induces myoclonus but partial 5-HT,A agonists such as buspirone do not.
This pilot study was intended as a preliminary step in evaluation of the possible role of 5-HT,A receptor abnormalities in progressive myoclonus epilepsy. The 5-HT,A receptor is key to the 5-HT containing raphe neurons on which it is located, because its stimulation decreases cell firing. The activity of these neurons may be especially important in brainstem-mediated myoclonus, but the raphe nuclei also project widely to forebrain and spinal cord. Buspirone (Buspar) is the first clinically used 5-HT A agonist of its class, widely prescribed as an anxiolytic.2 Since anxiety increases myoclonus in our patient population, we also hypothesised that they may benefit from an anxiolytic. Much evidence suggests buspirone exerts its clinical effect by stimulating pre-synaptic 5-HT,A receptors.
Two male and two female patients, aged 15-22 years, with progressive myoclonus epilepsy who had failed conventional therapy were identified. Standard diagnostic tests had been performed including muscle enzyme histochemistry. All were taking one or more anticonvulsants (valproic acid, clonazepam, lorazepam, or phenobarbital) for control of seizures, but none of the drug doses were changed during the study. Each patient had prominent action myoclonus, some spontaneous myoclonus, and little or no cerebellar ataxia. None of the patients were seizure-free for more than a few months before the start of the study. All had therapeutic anticonvulsant levels before and during the study.
Patients were enrolled in an off label uncontrolled dose-ranging trial of buspirone using anxiolytic dose guidelines. The starting dose was 5 mg orally three times a day. The incidence of irritability and sedation in our patients was higher than the 2% and 10% of 477 cases in the Physician's Desk Reference, respectively. There may have been less dizziness (12% in PDR).
This uncontrolled observational study in a small number of patients suggests that buspirone does not help and may exacerbate myoclonus in progressive myoclonus epilepsy. Worsening of myoclonus was not explained by decreased anticonvulsant levels, and there are no experimental data to support an interaction between buspirone and anticonvulsants. Although a fluctuating baseline of patients with progressive myoclonus epilepsy could give the false impression of drug-induced exacerbation, the patients improved when buspirone was discontinued.
The data should be viewed as positive findings for several reasons. Any response to buspirone suggests that the 5-HTIA somatodendritic autoreceptors are intact, and by inference, that 5-HT-containing raphe neu- 
